• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.

作者信息

Lyski Zoe L, Kim Myung S, Xthona Lee David, Raué Hans-Peter, Raghunathan Vikram, Griffin Janet, Ryan Debbie, Brunton Amanda E, Curlin Marcel E, Slifka Mark K, Messer William B, Spurgeon Stephen E

机构信息

Department of Molecular Microbiology and Immunology and.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.

出版信息

Blood Adv. 2022 Feb 22;6(4):1207-1211. doi: 10.1182/bloodadvances.2021006633.

DOI:10.1182/bloodadvances.2021006633
PMID:34872103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8651482/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a0/8864650/39566d09461d/advancesADV2021006633f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a0/8864650/39566d09461d/advancesADV2021006633f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00a0/8864650/39566d09461d/advancesADV2021006633f1.jpg

相似文献

1
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对新冠病毒mRNA疫苗的细胞免疫和体液免疫反应
Blood Adv. 2022 Feb 22;6(4):1207-1211. doi: 10.1182/bloodadvances.2021006633.
2
Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者接种BNT162b2 mRNA新冠疫苗后六个月的抗体持久性
Blood Adv. 2022 Jan 11;6(1):148-151. doi: 10.1182/bloodadvances.2021005998.
3
Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.BNT162b2 mRNA COVID-19 疫苗对慢性淋巴细胞白血病患者体液和细胞免疫的影响。
Hematol Oncol. 2023 Feb;41(1):120-127. doi: 10.1002/hon.3077. Epub 2022 Sep 30.
4
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA 新冠病毒疫苗接种后长期血液透析患者中产生强烈细胞和体液免疫应答。
Front Immunol. 2022 Mar 23;13:845882. doi: 10.3389/fimmu.2022.845882. eCollection 2022.
5
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.慢性淋巴细胞白血病患者接种mRNA BNT162b2疫苗后针对严重急性呼吸综合征冠状病毒2的T细胞免疫反应：一项前瞻性开放标签临床试验的结果
Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300.
6
Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.在接受伊布替尼或利妥昔单抗治疗的患者中，对 SARS-CoV-2 mRNA 疫苗的细胞和体液免疫反应。
Clin Exp Med. 2023 Jun;23(2):371-379. doi: 10.1007/s10238-022-00809-0. Epub 2022 Mar 29.
7
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.单剂 COVID-19 疫苗对慢性淋巴细胞白血病患者中 SARS-CoV-2 奥密克戎 BA.2 变异株的体液和细胞功能应答。
Leuk Lymphoma. 2023 Apr;64(4):874-883. doi: 10.1080/10428194.2023.2183730. Epub 2023 Mar 12.
8
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对 SARS-CoV-2 的混合免疫。
Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4.
9
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
10
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.BNT162b2 mRNA COVID-19 疫苗在慢性淋巴细胞白血病患者中的疗效：血清学和细胞研究。
Chemotherapy. 2022;67(2):91-95. doi: 10.1159/000521229. Epub 2021 Dec 6.

引用本文的文献

1
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.甘露糖修饰的脂质磷酸钙纳米颗粒疫苗通过调节肿瘤微环境增强抗肿瘤免疫反应。
J Funct Biomater. 2024 Aug 16;15(8):229. doi: 10.3390/jfb15080229.
2
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
3

本文引用的文献

1
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）特异性记忆 B 细胞来自疾病严重程度不同的个体，可识别关注的 SARS-CoV-2 变体。
J Infect Dis. 2022 Mar 15;225(6):947-956. doi: 10.1093/infdis/jiab585.
2
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.抗CD20单克隆抗体对B细胞非霍奇金淋巴瘤患者接种BNT162b2疫苗血清学反应的影响
Leukemia. 2022 Feb;36(2):588-590. doi: 10.1038/s41375-021-01418-8. Epub 2021 Sep 20.
3
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
在接受利妥昔单抗治疗的自身免疫性疾病患者中，第二次和第三次接种 SARS-CoV-2 疫苗后的细胞和体液反应：特异性 T 细胞免疫持续时间更长，并对 SARS-CoV-2 再感染起到保护作用。
Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023.
4
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.CLL 患者异源 COVID-19 疫苗接种后的免疫应答分析。
Blood Adv. 2023 May 23;7(10):2214-2227. doi: 10.1182/bloodadvances.2022008445.
5
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia.卫星五号疫苗接种后慢性淋巴细胞白血病患者中产生的冠状病毒特异性抗体和 T 细胞应答。
Int J Mol Sci. 2022 Dec 27;24(1):416. doi: 10.3390/ijms24010416.
6
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对 SARS-CoV-2 疫苗的体液和细胞应答减弱。
Blood Adv. 2023 Sep 12;7(17):4728-4737. doi: 10.1182/bloodadvances.2022009164.
7
B-cell malignancies and COVID-19: a narrative review.B 细胞恶性肿瘤与 COVID-19：一篇叙述性综述。
Clin Microbiol Infect. 2023 Mar;29(3):332-337. doi: 10.1016/j.cmi.2022.10.030. Epub 2022 Nov 4.
8
Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination.慢性淋巴细胞白血病（CLL）患者接种异源新冠病毒疫苗后的免疫反应综合分析。
medRxiv. 2022 Sep 21:2022.09.21.22280205. doi: 10.1101/2022.09.21.22280205.
9
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies.三剂次mRNA新冠疫苗基础免疫系列在淋巴系统恶性肿瘤患者中的免疫原性
Open Forum Infect Dis. 2022 Aug 16;9(8):ofac417. doi: 10.1093/ofid/ofac417. eCollection 2022 Aug.
10
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry.国际细胞与基因治疗学会间充质基质细胞委员会关于克服新型冠状病毒肺炎间充质基质细胞疗法临床试验局限性的社论：建立全球登记册的时候了。
Cytotherapy. 2022 Nov;24(11):1071-1073. doi: 10.1016/j.jcyt.2022.07.010. Epub 2022 Aug 1.
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
血液恶性肿瘤患者对 SARS-CoV-2 疫苗的免疫原性较弱。
Blood Cancer J. 2021 Aug 10;11(8):142. doi: 10.1038/s41408-021-00534-z.
4
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.血液系统恶性肿瘤患者对2019冠状病毒病信使核糖核酸疫苗的反应欠佳：在后口罩时代需要保持警惕
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. doi: 10.1093/ofid/ofab353. eCollection 2021 Jul.
5
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
6
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.慢性淋巴细胞白血病患者在接受第一剂和第二剂 COVID-19 疫苗后的抗体反应。
Blood Cancer J. 2021 Jul 30;11(7):136. doi: 10.1038/s41408-021-00528-x.
7
Seroprevalence of Measles and Mumps Antibodies Among Individuals With Cancer.癌症患者麻疹和风疹抗体的血清阳性率。
JAMA Netw Open. 2021 Jul 1;4(7):e2118508. doi: 10.1001/jamanetworkopen.2021.18508.
8
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.慢性淋巴细胞白血病患者的COVID-19：生存结果改善及管理策略更新
Blood. 2021 Nov 4;138(18):1768-1773. doi: 10.1182/blood.2021011841.
9
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
10
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.单剂 Ad26.COV2.S 疫苗预防新冠病毒的安全性和有效性。
N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21.